• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

家族性高胆固醇血症:儿童和青少年的诊断与管理策略述评。

Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents.

机构信息

Department of Cardiology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.

出版信息

Vasc Health Risk Manag. 2021 Feb 17;17:59-67. doi: 10.2147/VHRM.S266249. eCollection 2021.

DOI:10.2147/VHRM.S266249
PMID:33628029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7898200/
Abstract

Familial hypercholesterolemia (FH) is a relatively common inherited disorder caused by deleterious mutation(s) in the low-density lipoprotein (LDL) receptor or its associated genes. Given its nature as a heritable disease, any useful screening scheme, including universal, and cascade screening, allows for the early identification of patients with FH. Another important aspect to note is that early diagnosis associated with appropriate treatment can promote better prognosis. However, most clinical diagnostic criteria for adults have adopted clinical elements, such as physical xanthomas and family history, both of which are usually obscure and/or difficult to obtain in children and adolescents. Moreover, LDL cholesterol levels fluctuating considerably during adolescence, hindering the timely diagnosis of FH. In addition, recent advancements in human genetics have revealed several types of FH, including conventional monogenic FH, polygenic FH caused by common single nucleotide variations (SNV) accumulation associated with elevated LDL cholesterol, and oligogenic FH with multiple deleterious genetic variations leading to substantially elevated LDL cholesterol. The aforementioned findings collectively suggest the need for amassing information related to genetics and imaging, in addition to classical clinical elements, for the accurate diagnosis of FH in this era of personalized medicine. The current narrative review summarizes the current status of the clinical and genetic diagnosis of FH in children and adolescents, as well as provide useful management strategies for FH in children and adolescents based on currently available clinical evidence.

摘要

家族性高胆固醇血症(FH)是一种相对常见的遗传性疾病,由低密度脂蛋白(LDL)受体或其相关基因的有害突变引起。鉴于其遗传性疾病的性质,任何有用的筛查方案,包括普遍筛查和级联筛查,都可以早期识别 FH 患者。另一个需要注意的重要方面是,早期诊断和适当的治疗可以促进更好的预后。然而,大多数成人临床诊断标准都采用了临床元素,如身体黄瘤和家族史,这些元素在儿童和青少年中通常是模糊的和/或难以获得的。此外,青春期 LDL 胆固醇水平波动较大,阻碍了 FH 的及时诊断。此外,人类遗传学的最新进展揭示了几种 FH 类型,包括传统的单基因 FH、由与 LDL 胆固醇升高相关的常见单核苷酸变异(SNV)积累引起的多基因 FH,以及多个有害遗传变异导致 LDL 胆固醇显著升高的寡基因 FH。上述发现共同表明,在个性化医疗时代,除了经典的临床元素外,还需要积累与遗传学和影像学相关的信息,以便准确诊断 FH。本综述总结了目前儿童和青少年 FH 的临床和遗传诊断现状,并根据目前可用的临床证据,为儿童和青少年 FH 提供了有用的管理策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d3/7898200/a723b43f0db8/VHRM-17-59-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d3/7898200/d87a81b21c49/VHRM-17-59-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d3/7898200/a723b43f0db8/VHRM-17-59-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d3/7898200/d87a81b21c49/VHRM-17-59-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d3/7898200/a723b43f0db8/VHRM-17-59-g0002.jpg

相似文献

1
Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents.家族性高胆固醇血症:儿童和青少年的诊断与管理策略述评。
Vasc Health Risk Manag. 2021 Feb 17;17:59-67. doi: 10.2147/VHRM.S266249. eCollection 2021.
2
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.降低家族性高胆固醇血症患者的心血管风险:风险预测和血脂管理。
Prog Cardiovasc Dis. 2019 Sep-Oct;62(5):414-422. doi: 10.1016/j.pcad.2019.10.003. Epub 2019 Oct 25.
3
Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).希腊临床诊断为家族性高胆固醇血症的 1093 例患者的特征和管理:来自希腊家族性高胆固醇血症登记处(HELLAS-FH)的数据。
Atherosclerosis. 2018 Oct;277:308-313. doi: 10.1016/j.atherosclerosis.2018.08.017.
4
Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.捷克共和国和斯洛伐克杂合子家族性高胆固醇血症患者的真实 LDL-C 治疗目标达成情况:PLANET 登记研究结果。
Atherosclerosis. 2018 Oct;277:355-361. doi: 10.1016/j.atherosclerosis.2018.08.008.
5
Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA).家族性高胆固醇血症的诊断和管理共识文件,来自意大利动脉粥样硬化学会 (SISA)。
Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):1819-1836. doi: 10.1016/j.numecd.2024.05.002. Epub 2024 May 7.
6
Latvian registry of familial hypercholesterolemia: The first report of three-year results.拉脱维亚家族性高胆固醇血症登记处:三年结果的首次报告。
Atherosclerosis. 2018 Oct;277:347-354. doi: 10.1016/j.atherosclerosis.2018.06.011.
7
Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.家族性高胆固醇血症的基因检测:对诊断、治疗和心血管风险的影响。
Eur J Prev Cardiol. 2019 Aug;26(12):1262-1270. doi: 10.1177/2047487319829746. Epub 2019 Feb 12.
8
Familial hypercholesterolemia treatments: Guidelines and new therapies.家族性高胆固醇血症的治疗:指南和新疗法。
Atherosclerosis. 2018 Oct;277:483-492. doi: 10.1016/j.atherosclerosis.2018.06.859.
9
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.美国杂合子家族性高胆固醇血症成人患者的治疗差距:来自CASCADE-FH注册研究的数据
Circ Cardiovasc Genet. 2016 Jun;9(3):240-9. doi: 10.1161/CIRCGENETICS.116.001381. Epub 2016 Mar 24.
10
Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.儿童家族性高胆固醇血症的普遍筛查:斯洛文尼亚模式和文献回顾。
Atherosclerosis. 2018 Oct;277:383-391. doi: 10.1016/j.atherosclerosis.2018.06.858.

引用本文的文献

1
Familial Hypercholesterolemia: A Comprehensive Review of Advances in Treatment Strategies and the Role of Patient Beliefs.家族性高胆固醇血症:治疗策略进展与患者信念作用的全面综述
Cureus. 2025 Jan 26;17(1):e78032. doi: 10.7759/cureus.78032. eCollection 2025 Jan.
2
Lipids dysregulation in diseases: core concepts, targets and treatment strategies.疾病中的脂质失调:核心概念、靶点与治疗策略。
Lipids Health Dis. 2025 Feb 21;24(1):61. doi: 10.1186/s12944-024-02425-1.
3
Statins in Children, an Update.他汀类药物在儿童中的应用:更新。

本文引用的文献

1
Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events.家族性高胆固醇血症级联筛查对心血管事件的预后影响。
J Clin Lipidol. 2021 Mar-Apr;15(2):358-365. doi: 10.1016/j.jacl.2020.12.012. Epub 2021 Jan 4.
2
The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review.他汀类药物在家族性高胆固醇血症儿童和青少年中的作用:系统评价。
J Pediatr Health Care. 2021 May-Jun;35(3):292-303. doi: 10.1016/j.pedhc.2020.11.007. Epub 2020 Dec 17.
3
Case Report: Liver Transplantation in Homozygous Familial Hypercholesterolemia (HoFH)-Long-Term Follow-Up of a Patient and Literature Review.
Int J Mol Sci. 2023 Jan 10;24(2):1366. doi: 10.3390/ijms24021366.
4
The Assessment of Carotid Atherosclerotic Plaque among Young Patients with Familial Hypercholesterolemia.年轻家族性高胆固醇血症患者颈动脉粥样硬化斑块评估。
Intern Med. 2022;61(21):3165-3169. doi: 10.2169/internalmedicine.9249-21. Epub 2022 Nov 1.
5
Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report.家族性高胆固醇血症的表型与基因级联筛查:一例报告
Front Cardiovasc Med. 2022 Aug 25;9:982607. doi: 10.3389/fcvm.2022.982607. eCollection 2022.
6
Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.使用定制 NGS .panel 鉴定家族性高胆固醇血症儿科患者中的新遗传决定因素。
Genes (Basel). 2022 Jun 1;13(6):999. doi: 10.3390/genes13060999.
7
Recent Advances on Familial Hypercholesterolemia in Children and Adolescents.儿童和青少年家族性高胆固醇血症的最新进展
Biomedicines. 2022 Apr 30;10(5):1043. doi: 10.3390/biomedicines10051043.
8
Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?动脉粥样硬化的治疗策略与化学预防:我们知道什么以及将何去何从?
Pharmaceutics. 2022 Mar 28;14(4):722. doi: 10.3390/pharmaceutics14040722.
9
Individualized Treatment for Patients With Familial Hypercholesterolemia.家族性高胆固醇血症患者的个体化治疗
J Lipid Atheroscler. 2022 Jan;11(1):39-54. doi: 10.12997/jla.2022.11.1.39. Epub 2022 Jan 3.
10
Treatment of Dyslipidaemia in Children.儿童血脂异常的治疗
Biomedicines. 2021 Aug 24;9(9):1078. doi: 10.3390/biomedicines9091078.
病例报告:纯合子家族性高胆固醇血症(HoFH)患者的肝移植——1例患者的长期随访及文献综述
Front Pediatr. 2020 Oct 9;8:567895. doi: 10.3389/fped.2020.567895. eCollection 2020.
4
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.依洛尤单抗在儿科杂合子家族性高胆固醇血症中的应用。
N Engl J Med. 2020 Oct 1;383(14):1317-1327. doi: 10.1056/NEJMoa2019910. Epub 2020 Aug 29.
5
Evinacumab for Homozygous Familial Hypercholesterolemia.依洛尤单抗治疗纯合子家族性高胆固醇血症。
N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.
6
Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.全球家族性高胆固醇血症患病率的Meta 分析:1100 万例患者研究
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566. doi: 10.1016/j.jacc.2020.03.057.
7
Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology.低密度脂蛋白胆固醇水平不能过低:来自临床试验、人类遗传学和生物学的考虑。
J Atheroscler Thromb. 2020 Jun 1;27(6):489-498. doi: 10.5551/jat.RV17040. Epub 2020 Apr 30.
8
Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials.他汀类药物在家族性高胆固醇血症儿童和青少年中的疗效与安全性:一项随机对照试验的系统评价和荟萃分析
Endocrine. 2020 Aug;69(2):249-261. doi: 10.1007/s12020-020-02302-8. Epub 2020 Apr 24.
9
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.长期依洛尤单抗治疗家族性高胆固醇血症患者的疗效。
J Am Coll Cardiol. 2020 Feb 18;75(6):565-574. doi: 10.1016/j.jacc.2019.12.020.
10
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.《心脏病与卒中统计-2020 更新:来自美国心脏协会的报告》。
Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.